Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science

Metabolic (dysfunction)-associated fatty liver disease (MAFLD) affects a third of the population and is a leading cause of liver-related death. Since no effective treatments exist, novel approaches to drug development are required. Unfortunately, outdated terminology and definitions of the disease a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fouad, Yasser, Palmer, Melissa, Chen, Minjun, Regev, Arie, Banerjee, Rajarshi, Myers, Rob, Riccio, Robert, Torstenson, Richard, Younes, Ramy, Arora, Puneet S., Landgren, Henrik, Karsdal, Morten A., Blake, Martin, Shapiro, David A., Gruss, Hans-Juergen, Sheikh, Muhammad Y., Attia, Dina, Bollipo, Steven, Smith, Alastair D., Freilich, Bradley, Gish, Robert G., Schuppan, Detlef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039717/
https://www.ncbi.nlm.nih.gov/pubmed/35528969
http://dx.doi.org/10.14218/JCTH.2021.00408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039717/
https://www.ncbi.nlm.nih.gov/pubmed/35528969
http://dx.doi.org/10.14218/JCTH.2021.00408

Ejemplares similares